CD274 and colorectal carcinoma: Furthermore, evaluation of cabozantinib in combination with the anti-PD-L1 durvalumab with or without tremelimumab in advanced chemo-refractory pMMR/MSS gastroesophageal cancer and other gastrointestinal malignancies including CRC is currently ongoing in a Phase I/II trial (CAMILLA trial, NCT03539822).